GMP-SM-1 | 216501-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: GMP-SM-1
• 英文别名: ethyl 1,2-difluoro-4-oxo-4H-pyrido[3,2,1-kl]benzo[g]-phenoxazine-5-carboxylate；Ethyl 14,15-difluoro-18-oxo-12-oxa-1-azapentacyclo[11.7.1.02,11.04,9.017,21]henicosa-2,4,6,8,10,13(21),14,16,19-nonaene-19-carboxylate
• CAS: 216501-20-1
• 化学式: C₂₂H₁₃F₂NO₄
• 分子量: 393.346
• InChiKey: AKHMWYKXBKVKBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  GMP-SM-1 在 吡啶 、 盐酸 、 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 40.5h， 生成 6-(3-Amino-pyrrolidin-1-yl)-5-fluoro-3-oxo-3H-7-oxa-13b-aza-benzo[de]naphthacene-2-carboxylic acid; hydrochloride
  参考文献：
  名称：

  Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model

  摘要：

  A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.

  DOI：

  10.1021/jm980265c
• 作为产物：
  描述：

  3-amino-naphthalen-2-ol; hydrochloride 在 吡啶 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.75h， 生成 GMP-SM-1
  参考文献：
  名称：

  Design of New Topoisomerase II Inhibitors Based upon a Quinobenzoxazine Self-Assembly Model

  摘要：

  A new class of pyridobenzophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy. These compounds were designed based on a proposed model of a quinobenzoxazine self-assembly complex on DNA. They showed excellent inhibitory effects on several tumor cell lines with nanomolar IC50 values. Their cytotoxic potency correlates with their ability to unwind DNA and inhibit topoisomerase II.

  DOI：

  10.1021/jm980265c

文献信息

• Novel benzothiazole compounds and methods of use thereof
  申请人：Whitten P. Jeffrey

  公开号：US20060063761A1

  公开（公告）日：2006-03-23

  The present invention relates to methods of preparing compounds having formula (1), (2), (5), and ((6A)-(6D)) comprising contacting the corresponding ester, an amine with formula NHR 1 R 2 , and a Lewis acid having formula ML n , wherein L is a halogen atom or an organic radical, n is 3-5, and M is a group III elemental atom, a group IV elemental atom, As, Sb, V or Fe, wherein A, B, V, X, Z, W, R 1 , R 2 , R 5 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , and Z 8 are substituents. Z 4 , Z 5 , Z 6 , Z 7 , and Z 8 are substituents.

  本发明涉及制备具有式（1）、（2）、（5）和（（6A）-（6D））的化合物的方法，包括接触相应的酯、具有式NHR1R2的胺和具有式MLn的Lewis酸，其中L是卤素原子或有机基团，n为3-5，M为III族元素原子、IV族元素原子、As、Sb、V或Fe，其中A、B、V、X、Z、W、R1、R2、R5、Z1、Z2、Z3、Z4、Z5、Z6、Z7和Z8为取代基。Z4、Z5、Z6、Z7和Z8为取代基。
• Substituted quinobenzoxazine analogs
  申请人：Cylene Pharmaceuticals, Inc.

  公开号：US07141565B1

  公开（公告）日：2006-11-28

  The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.

  本发明涉及具有以下一般式的喹诺苯并噁唑类似物： 并且其药学上可接受的盐，酯和前药； 其中A，U，V，W，X和Z是取代基。 本发明还涉及使用这些化合物的方法。
• SUBSTITUTED QUINOBENZOXAZINE ANALOGS
  申请人：Whitten Jeffrey P.

  公开号：US20080261963A1

  公开（公告）日：2008-10-23

  The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.

  本发明涉及具有以下一般式的喹诺苯并噁唑类似物，以及其药学上可接受的盐、酯和前药： 其中A、U、V、W、X和Z是取代基。本发明还涉及使用这些化合物的方法。
• HYDRAZIDE COMPOUNDS AND USES THEREOF
  申请人：Schwaebe Michael

  公开号：US20110065687A1

  公开（公告）日：2011-03-17

  This application relates to certain novel polycyclic compounds that interact with quadruplex-forming regions of polynucleotides and thereby inhibit translation of genetic information into polypeptides. These compounds can thus provide anticancer and antibacterial and antiviral effects. The invention includes novel compounds and pharmaceutical compositions, and methods of using them to treat cancer and other conditions.

  该应用涉及与多聚核苷酸四链体形成区域相互作用的某些新型多环化合物，从而抑制遗传信息转化为多肽。这些化合物可以提供抗癌、抗菌和抗病毒效果。发明包括新型化合物和药物组合物，以及使用它们治疗癌症和其他疾病的方法。
• WO2008/131134
  申请人：——

  公开号：——

  公开（公告）日：——